Schubert & Co’s Halozyme HALO Stock Holding History

Schubert & Co’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-34	Closed	-$1.3K	–	665
2023 Q1	$1.3K	Sell	34 -62	-65%	-$2.91K	﹤0.01%	1089
2022 Q4	$5.46K	Buy	96 +49	+104%	+$2.51K	0.01%	399
2022 Q3	$2K	Sell	47 -14	-23%	-$619	﹤0.01%	809
2022 Q2	$3K	Buy	61 +43	+239%	+$1.86K	﹤0.01%	592
2022 Q1	$1K	Buy	18 +7	+64%	+$249	﹤0.01%	716
2021 Q4	$0	Buy	+11	New	+$411	﹤0.01%	1118

Other funds holding HALO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Schubert & Co's HALO Position: Q2 2023 in Review

Schubert & Co sold out of Halozyme (HALO) in Q2 2023, closing a stake of 34 shares — an estimated $1.3K sold.

Schubert & Co first reported a position in HALO in Q4 2021 and held it in 6 quarters. The position peaked at $5.46K in Q4 2022. 370 funds tracked by Wall St. Rank hold HALO as of Q2 2023.

Schubert & Co reported no remaining Halozyme position as of Q2 2023 after selling out during the quarter.
Schubert & Co sold 34 Halozyme shares in Q2 2023, an estimated $1.3K.
Schubert & Co first reported a position in Halozyme in Q4 2021 and held it in 6 quarters.
Schubert & Co's Halozyme position peaked at $5.46K in Q4 2022.
370 funds tracked by Wall St. Rank held Halozyme as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.